Cys-mcMMAD is a maleimide-based ADC linker with a cytotoxic monomethyl auristatin derivative, optimized for cysteine conjugation sites in antibody-drug conjugates. This molecule improves ADC stability and drug release profiles in cancer treatment. Keywords: maleimide linker, cysteine conjugation, MMA derivative, ADC payload.
Structure of
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
-- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Cys-mcMMAD, a potent cytotoxic payload utilized in antibody-drug conjugates (ADCs) for precision cancer therapy. Here are four key applications of Cys-mcMMAD:
Targeted Cancer Therapy: Integral to ADC development, Cys-mcMMAD is fused with antibodies that exhibit precise recognition and binding to malignant cells, facilitating targeted destruction. Upon interaction, the ADC penetrates the cancer cell, releasing the cytotoxic Cys-mcMMAD and triggering cell demise. This strategic approach minimizes harm to healthy tissues while amplifying the efficacy of cancer treatment.
Drug Development: Within the realm of preclinical investigations, researchers harness Cys-mcMMAD to assess the therapeutic potential of novel cancer-targeting antibodies. Through conjugating antibodies with Cys-mcMMAD, they scrutinize the specificity, potency, and safety of the ADCs across diverse cancer models. These studies play a pivotal role in refining ADC formulation before progression to clinical experimentation.
Mechanism of Action Studies: Cys-mcMMAD functions as a key tool in dissecting the intracellular mechanisms engaged by ADCs. By monitoring the cellular uptake, trafficking, and processing of Cys-mcMMAD, scientists unveil the intricate processes through which these conjugates enact cancer cell death. This comprehension aids in identifying determinants impacting ADC efficacy and resistance patterns.
Combination Therapy: The evaluation of Cys-mcMMAD-based ADCs, in conjunction with other therapeutic modalities, seeks to elevate overall treatment efficacy. Pairing ADCs with immune checkpoint inhibitors or traditional chemotherapeutics fosters synergistic effects, bolstering the therapeutic impact and potentially circumventing resistance mechanisms. This integrative strategy aims to offer robust and multifaceted approaches to combatting cancer.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00026 | Mc-MMAD | 1401963-15-2 | |
BADC-00024 | Vc-MMAD | 1401963-17-4 | |
BADC-00016 | Vat-Cit-PAB-MMAD | 1415329-13-3 | |
BADC-00310 | MMAD hydrochloride | 173441-26-4 | |
BADC-00309 | MMAD | 203849-91-6 | |
BADC-00728 | OSu-Glu-vc-PAB-MMAD | ||
BADC-00736 | MC-va-PAB-MMAD | ||
BADC-00739 | MC-vc-PAB-MMAD | ||
BADC-00757 | DBCO-PEG4-vc-PAB-MMAD | ||
BADC-00843 | D8-MMAD |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.